Ovarian cancer metastasis study identifies important protein with potential as diagnostic tool and treatment option
Advanced ovarian cancer most commonly metastasizes to the omentum, a layer of fatty tissue that wraps around and protects internal organs in the abdomen, but the reasons for this have not been well-understood. In a new study, MD Anderson researchers discovered that a protein called omentin, or ITLN1, works to prevent metastasis of the cancer cells, but it is lost as the cancer develops.
Their preclinical findings, published in...
Ovarian cancer analysis identifies potential treatment biomarkers
MD Anderson researchers have identified potential biomarkers for the response of high-grade serous ovarian cancers (HGSC) to surgical resection...
Ovarian Cancer Moon Shot works to broaden immunotherapy impact
Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have...
Breast, ovarian cancer trials find targeted therapies provide benefit over chemotherapy
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival (PFS) and response rates compared to the standard of care for women with certain types of breast and ovarian cancers. These studies were presented today in Barcelona as late-breaking abstracts at the European Society for Medical Oncology Congress 2019. As the...
Blocking protein reduces fibrosis, thwarts ovarian and pancreatic cancer
Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...
What’s next for targeting cancer DNA repair with PARP inhibitors?
DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...
Ovarian Moon Shot team battles highly recurrent disease
September is Ovarian Cancer Awareness Month, an annual time to bring attention to the impact of the disease. This year, more than 22,000 women...
Innovative study delivers genetic screening to your doorstep
When Elizabeth White started a new job as executive director of the Michigan Ovarian Cancer Alliance in 2017, she decided it...
Identifying an enzyme that keeps ovarian cancer safe from immune attacks
A study of high-grade ovarian cancer has shown the enzyme protein kinase C iota (PRKCI) to be an ovarian oncogene, suggesting PRKCI inhibition...
Hormone therapy shows big promise for ovarian cancer patients
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...